Onco Actu du 18 juillet 2017

	2.5 Etiologie - Gènes
‘Could more cancers be caused by inherited faulty genes than we now think?’ [Cancer Research UK] “As we find out more through research, the proportion of cancers that we can explain by inherited genetic changes will likely continue to go up as it already has in recent year.The proportion itself won’t change though; it’s the proportion we understand that may change."
	2.6 Etiologie - Environnement
EU will only extend glyphosate license with national backing [Reuters] Andriukaitis told reporters during a meeting of EU agriculture ministers that he had no reason to doubt that glyphosate was safe but it was up to national governments to agree to extend the approval.
	3.1 Tabac
Tobacco companies diversify into ‘pharmaceuticals’ [Reuters] “The same hand that’s creating the problem is attempting to create the solution,” lead author Yogi Hendlin said in a phone interview. “But their solution is long-term nicotine maintenance, rather than total tobacco cessation.”
	4. Dépistage, diagnostic et pronostic
With Cancer Screening, Better Safe Than Sorry? [NY Times] “Older adults with limited life expectancy are frequently screened for cancer even though it exposes them to risks of screening with minimal benefits.”
	5. Traitements
Immunosuppression underlies resistance to anti-angiogenic therapy [Mass. General Hospital] Mass. General study identifies role of non-classical monocytes in blocking action of anti-cancer drugs.
Research may unlock statins cancer-fighting ability [Pharmafile] Many previous studies have shown that statins are able to have an impact on cancer cells but the results have yet to be seen in human trials. Keele University has now conducted research that could point towards why they have proved ineffective so far.
Scientists make breakthrough in reversing treatment resistance in blood cancer patients [university of Southampton] In contrast to other immune system stimulators tested, one particular class of reagents called STING agonists were consistently able to stimulate macrophages, reverse the resistance and eliminate lymphoma cells in both mice and human cells in the laboratory when used in combination with monoclonal antibodies.
	5.12 Immunothérapies
Merck's new Keytruda flat dose could add $1B each year to U.S. healthcare spending [FiercePharma] The company adopted the flat dose “without any clinical or biologic rationale,” according to Bach and Saltz.
	5.2 Pharma
What really happened with Pascal Soriot's rumored move to Teva? [FiercePharma] You could call the whole episode a rumor-fueled charade, fed by AZ’s two-day silence on the subject. But though there are exceptions, we’ve found over the years that rumors typically don’t arise out of nowhere.
	5.3 Traitements - FDA, EMA, NICE...
Gottlieb Lays Out Plans to Bolster FDA's Staff [RAPS] However, if the user fee agreements are not reauthorized by 1 August 2017, FDA's workforce could suffer a significant blow as the agency would need to begin sending layoff warnings to thousands of employees.
FDA’s Scott Gottlieb is fielding a new team of recruiters to start scouting top talent [EndPoints] Without a legion of regulators to help clear the backlog of generic applications, Gottlieb’s plan to accelerate a wave of cheap new drugs to the market will be hampered by a lack of hands on deck.
Building a Strong FDA Workforce to Bring Scientific Advances to Patients [FDA Voice] To take on this new effort, we’re establishing a dedicated group of full-time staff with the responsibility to ensure that we reliably and predictably identify, recruit, and efficiently hire the scientific personnel the Agency needs.
	5.3.4 Traitements - AMM (FDA, EMA)
Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib [Puma] The ODAC vote was based on a review of the clinical development program that included 11 trials in breast cancer and represented approximately 2,000 patient years’ experience.
FDA approves new treatment to reduce the risk of breast cancer returning [FDA] The safety and efficacy of Nerlynx were studied in a randomized trial of 2,840 patients with early-stage, HER2-positive breast cancer who completed treatment with trastuzumab within the previous two years.
Puma wins big FDA OK for neratinib after running the gamut with investors [EndPoints] Concerned about the high rate of Grade 2 and Grade 3 diarrhea in the clinical studies, regulators are telling physicians to stop using the drug if their patient experiences Grade 4 diarrhea or Grade 2 after a maximum dose reduction.
U.S. FDA approves Puma Biotech's breast cancer treatment [Reuters] The stock has so far more than doubled in value since May when the FDA said in a preliminary review that Puma Biotech's drug, neratinib, appeared to be effective.
	5.4 Traitements - Economie
How the NHS became embroiled in a global drugs price clash [The Telegraph] Simon Stevens, chief executive of NHS England, argued it was “an incoherent stance” for the industry to insist all medicines be made available within 90 days and this would mean “having to make billions of pounds of cuts elsewhere” in the NHS budget.
The art of the deal? Why a money-back guarantee for drugs is a bad idea [STAT] “Refunds don’t lower the price of the drug. Besides, telling me I’ll get a money-back guarantee doesn’t do much good if I have a heart attack and end up dead.”
	6. Lutte contre les cancers
Proton beam therapy is arriving in the UK: what does that mean for patients? [Cancer Research UK] Ultimately, that doesn’t mean the treatment will be more likely to cure their disease than conventional radiotherapy. But it may be a safer way to deliver the therapy.
When A Brilliant Mathematician Dies From Breast Cancer At Age 40 [Forbes] What conclusions about cancer can one draw from the death of this one woman, a mathematician, from metastatic disease at age 40? None. Only sadness.
	6.1 Observation
‘Burden of cancer’ increasing as UK trails behind Europe in cancer care [ABPI] ​​​​​​​​​​Despite the increasing burden of cancer on society, the UK spends over 20 per cent less per person on cancer than the top five EU economies; 20 per cent less of its total health budget on cancer than the rest of the EU; and 10 per cent less of its GDP on healthcare than the rest of the EU.
UK cancer survival rates lag behind those of other European countries – study [The Guardian] The report is the latest to highlight the problem, with previous research suggesting that UK survival rates for breast cancer are a decade behind countries including France and Sweden.
Don't avoid vasectomy for fear of prostate cancer: study [Reuters] For the review, the researchers looked through the medical literature and found 53 studies examining the link between vasectomy and prostate cancer risk. Overall, the data did not suggest a link between vasectomy and fast-growing, advanced or deadly prostate cancer.
	6.10.1 Politiques (USA)
Sen. Ron Johnson threatens to obstruct passage of the bill funding the FDA if “right-to-try” language isn’t added [Respectful Insolence] Right-to-try is a Trojan horse designed to gut the FDA’s authority to regulate and approve experimental therapeutics.